Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus and Temozolomide in Metastatic Melanoma
NCT00521001Phase 2Completed
- Sponsor
- Cancer and Leukemia Group B
- Start
- Jan 2008
- Primary completion
- Dec 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of everolimus in melanoma, sponsored by Cancer and Leukemia Group B. Primary endpoint: 9-week Progression-free Survival Rate. Started Jan 2008; status: completed.
02
Drugs
everolimus
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00521001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00521001.